This 103-page report is designed to help suppliers identify and evaluate emerging opportunities for further automating NAT methods in order to facilitate their penetration into the routine clinical laboratory market. Some instrumentation is already available on the market, e.g., DNA extractors, DNA synthesizers, thermal cyclers, robotic work-stations, and automated DNA probe analysis systems. The report reviews current instrumentation technologies, and compares features of leading molecular diagnostics analyzers marketed by Abbott, Beckman Coulter, BD, Bio-Rad, Gen-Probe, Tecan, Trinity Biotech and other manufacturers.
This report also presents strategic assessments of current and emerging suppliers of NAT products, including their sales, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.
Contains 103 pages
This report also presents strategic assessments of current and emerging suppliers of NAT products, including their sales, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.
Contains 103 pages
Companies Mentioned
- Abbott
- Affymetrix
- Agilent Technologies
- Applied Gene Technologies
- Arca Biopharma
- Beckman Coulter/Danaher
- Becton Dickinson
- Biokit
- bioMerieux
- Bio-Rad
- Biotest
- Cepheid
- Decode Genetics
- Diadexus
- Eiken Chemical
- Elitech Group
- Enzo Biochem
- Exact Sciences
- Fujirebio
- Grifols
- Hologic
- Illumina
- LabCorp
- Leica Biosystems
- Li-Cor Biosciences
- Myriad Genetics
- Ortho-Clinical Diagnostics
- PerkinElmer
- Proteome Sciences
- Qiagen
- Roche
- Scienion
- Sequenom
- Shimadzu
- Siemens Healthineers
- Sierra Molecular
- Takara Bio
- Tecan Group
- Thermo Fisher
